t200 optical biosensor instrument  (Biacore)

Journal: Cancers

Article Title: A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action

doi: 10.3390/cancers13051027

Figure Lengend Snippet: Binding activities of BsAb: ( A ) Surface plasmon resonance sensor grams showing the binding kinetics of anti-EGFR/VEGFR2 BsAb to antigens EGFR and VEGFR2 as detected by a Biacore T200 optical biosensor instrument. Black line represents the constant concentration of anti-EGFR/VEGFR2 BsAb (8 µg/mL) and colored lines represent the nM concentrations of antigens (EGFR or VEGFR2). ( B ) ELISA binding assay showing that anti-EGFR/VEGFR2 BsAb binds to both EGFR and VEGFR2 comparable with cetuximab and ramucirumab, respectively. ( C ) Flow cytometry experiment was performed to assess the binding of anti-EGFR/VEGFR2 BsAb, cetuximab, ramucirumab with cell surface EGFR and VEGFR2 expressed on MDA-MB-231, BT-20, MDA-MB-468 and HUVEC cells. Human IgG was used as isotype control. ( D ) Whole cell lysate of MDA-MB-231 cells was subjected to co-immunoprecipitation assay to assess the binding of anti-EGFR/VEGFR2 BsAb with EGFR and VEGFR2 comparable to parental antibodies. Unprocessed western blot images are available in .

Article Snippet: Surface plasmon resonance (SPR) measurements were performed for binding kinetics analyses with a Biacore T200 optical biosensor instrument (GE Healthcare, Piscataway, NJ, USA).

Techniques: Binding Assay, SPR Assay, Concentration Assay, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Co-Immunoprecipitation Assay, Western Blot